Navidea biopharmaceuticals completes full enrollment in phase 2b normative database study to support its rheumatoid arthritis program

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it has achieved full enrollment in its nav3-35 phase 2b clinical study titled “development of a normative database for rheumatoid arthritis (ra) imaging with tc99m tilmanocept.” establishing a healthy subject database is necessary to create a quantitative method f
NAVB Ratings Summary
NAVB Quant Ranking